A2AR antagonists confer neuroprotection in animal models of stroke, Parkinson’s and Alzheimer’s disease, and traumatic brain injury, most likely by controlling neuroinflammation, excitotoxic neuronal damage, and synaptopathy [20,21]. This evidence concerns the gene ADORA2A and early-onset autosomal dominant Alzheimer disease.